ArticleHeliyon2024
Preparation and optimization of niosome encapsulated meropenem for significant antibacterial and anti-biofilm activity against methicillin-resistant
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Surfactant-Engineered Niosomal Antibiotic Systems for Biofilm-Associated Infections: Design Principles and Translational Perspectives.International journal of nanomedicine · 2026Review
- Deciphering the efficacy of staphyloxanthin-encapsulated niosomal nanovesicles to attenuate biofilm formation, quorum sensing, and meropenem persistence in Acinetobacter baumannii.BMC microbiology · 2025Article
- Enhanced antibacterial activity of 3D-printed niosome-curcumin/ceftizoxime scaffolds against drug-resistant pathogens.BMC microbiology · 2025Article
- Evaluating the potential of travoprost-thymoquinone co-loaded liposomes: a glaucomatous rabbit model study.Therapeutic delivery · 2025Article
- Physicochemical Characteristics of Phospholipid Vesicles for Spirulina-Based Dietary Supplement Delivery.Molecules (Basel, Switzerland) · 2025Article
- Investigation of the preparation of iron sulfate-loaded niosomes by an experimental novel method.Scientific reports · 2025Article
- Nanomedicine approaches to enhance the effectiveness of meropenem: a strategy to tackle antimicrobial resistance.Discover nano · 2025Review
- Investigating the effect of rosmarinic acid loaded magnetic nanoparticles against growth and biofilm formation ofIranian journal of veterinary research · 2025Article
- Optimization andAnti-inflammatory & anti-allergy agents in medicinal chemistry · 2025Article
- MAPLE-prepared graphene oxide-based coatings for improved orthopedic screws used in knee interventions.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: One of the targeted drug delivery systems is the use of nanocarriers, and one of these drug delivery systems is niosome. Niosome have a nano-vesicular structure and are composed of non-ionic surfactants. Objective: In this study, various niosome-encapsulated meropenem formulations were prepared. Subsequently, their antibacterial and anti-biofilm activities were evaluated against methicillin-resistant Methods: The physicochemical properties of niosomal formulations were characterized using a field scanning electron microscope, X-Ray diffraction, Zeta potential, and dynamic light scattering. Antibacterial and anti-biofilm activities were evaluated using broth microdilution and minimum biofilm inhibitory concentration, respectively. In addition, biofilm gene expression analysis was performed using quantitative Real-Time PCR. To evaluate biocompatibility, the cytotoxicity of niosome-encapsulated meropenem in a normal human diploid fibroblast (HDF) cell line was investigated using an MTT assay. Results: An F1 formulation of niosome-encapsulated meropenem with a size of 51.3 ± 5.84 nm and an encapsulation efficiency of 84.86 ± 3.14 % was achieved. The synthesized niosomes prevented biofilm capacity with a biofilm growth inhibition index of 69 % and significantly downregulated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.